|
|
|
|
|
terug |
Datum nieuwsfeit: 16-05-2008
Sorin Group Announces Letter of Intent to Leverage Greatbatch's MRI Technology for Its CRM Devices
( BW)(NY-SORIN-GROUP)(SRN.MI) Sorin Group Announces Letter of Intent
to Leverage Greatbatch's MRI Technology for Its CRM Devices
Business Editors/Health/Medical Writers
CLARENCE, N.Y.--(BUSINESS WIRE)--May 16, 2008--The Sorin Group
(MIL:SRN), and Greatbatch, Inc., (NYSE: GB) announced today the
execution of a letter of intent that will leverage Greatbatch's
eM-able(TM) technology in the Sorin Group's future cardiac rhythm
management (CRM) systems.
Catherine Picard, vice-president of Research & Development at
Sorin Group said: "We are very excited by the opportunity to leverage
Greatbatch's eM-able(TM) technology to accelerate our MRI program and
deliver MRI conditional systems to patients and physicians worldwide
in the shortest possible time."
Many patients implanted with a pacemaker or a defibrillator (ICD)
cannot take advantage of an MRI scan, because energy from this
life-saving technology can change how a device controls the heart,
damages the device or injures the heart tissue surrounding it.
MRI Conditional approved devices are critical to allow patients
with active implantable medical devices (AIMDs) to safely have an MRI
for diagnostic evaluation.
"As we see more patients receive AIMD's the need for MRI
conditional devices will continue to grow," said Mauricio Arellano,
senior vice president of Greatbatch's CRM & Neuromodulation business.
"This potential partnership with Sorin Group would meet that demand by
securing our technology in their next generation devices."
John Farrell, vice-president of Greatbatch's Therapy Delivery
business, added: "There has been extensive research and technology
development on eM-able(TM), and we are excited to get moving on our
first commercialization program that will bring the technology to
market, improving patient safety."
About eM-able(TM) Safe MRI Solutions
eM-able(TM) technology can be incorporated into implantable
devices to enhance safety for patients during MRI scans. Recently
issued patent 7,363,090 by the U.S. Patent and Trademark Office,
eM-able(TM) utilizes the technology of a band stop filter to attenuate
frequency during an MRI and eliminate heating of electrodes within an
implanted stimulation system.
For additional information go to
http://www.greatbatch.com/Medical/technologies.aspx.
About the Sorin Group
The Sorin Group (Bloomberg: SRN.IM; Reuters: SORN.MI), a world
leader in the development of medical technologies for cardiac surgery,
offers innovative therapies for cardiac rhythm dysfunctions,
interventional cardiology and the treatment of chronic kidney
diseases. The Sorin Group includes these brands: Dideco, CarboMedics,
COBE Cardiovascular, Stockert, Mitroflow, ELA Medical, Sorin
Biomedica, Bellco and Bellco-Soludia. At the Sorin Group 4,500
employees work to serve over 5,000 public and private treatment
centers in more than 80 countries throughout the world.
For more information, please visit: www.sorin.com or
www.sorin-crm.com.
--30--MD/ny*
CONTACT: Sorin Group
Martine Konorski, +33 (0)1 46 01 33 78
Director, Corporate Communications
Mobile: +33 (0)6 76 12 67 73
e-mail: martine.konorski@sorin.com
Disclaimer: Deze bekendmaking is officieel geldend in de originele
brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten
worden vergeleken met de tekst in de brontaal welke als enige,
juridische geldigheid beoogt.